These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38879852)

  • 1. Development and validation of an automatic machine learning model to predict abnormal increase of transaminase in valproic acid-treated epilepsy.
    Ma H; Huang S; Li F; Pang Z; Luo J; Sun D; Liu J; Chen Z; Qu J; Qu Q
    Arch Toxicol; 2024 Sep; 98(9):3049-3061. PubMed ID: 38879852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
    Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
    J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Valproic acid-induced idiosyncratic liver injury in 4 cases].
    Xiong H; Liu CT; Zhang YH; Bao XH; Jiang YW; Zhao H; Wu XP; Qin J
    Zhonghua Er Ke Za Zhi; 2012 Dec; 50(12):890-4. PubMed ID: 23324142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants p.Q1236H and p.E1143G in mitochondrial DNA polymerase gamma POLG1 are not associated with increased risk for valproate-induced hepatotoxicity or pancreatic toxicity: A retrospective cohort study of patients with epilepsy.
    Hynynen J; Pokka T; Komulainen-Ebrahim J; Myllynen P; Kärppä M; Pylvänen L; Kälviäinen R; Sokka A; Jyrkilä A; Lähdetie J; Haataja L; Mäkitalo A; Ylikotila P; Eriksson K; Haapala P; Ansakorpi H; Hinttala R; Vieira P; Majamaa K; Rantala H; Uusimaa J
    Epilepsia; 2018 Nov; 59(11):2125-2136. PubMed ID: 30255931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of metformin and sub-therapeutic dose of valproic acid prevent valproic acid-induced toxicity in animal model of epilepsy.
    Jamal M; Azam M; Simjee SU
    Drug Chem Toxicol; 2024 May; 47(3):287-295. PubMed ID: 36650908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA.
    Gopaul S; Farrell K; Abbott F
    Epilepsia; 2003 Mar; 44(3):322-8. PubMed ID: 12614387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential biomarker of fibroblast growth factor 21 in valproic acid-treated livers.
    Xu X; Guo C; Liang X; Li R; Chen J
    Biofactors; 2019 Sep; 45(5):740-749. PubMed ID: 31120577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Valproic Acid and Its Main Metabolites' Plasma Concentrations with Clinical Outcomes among Epilepsy Patients: A 10-Year Retrospective Study Based on Therapeutic Drug Monitoring.
    Li RT; Chen ZY; Tang SY; Wen DS; Ren RN; Zhang XX; Liu SZ; Zhou S; Wang XD; Zhou LM; Huang M
    Drug Metab Dispos; 2024 Feb; 52(3):210-217. PubMed ID: 38195521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
    Chen ZJ; Wang XD; Wang HS; Chen SD; Zhou LM; Li JL; Shu WY; Zhou JQ; Fang ZY; Zhang Y; Huang M
    Seizure; 2012 Mar; 21(2):110-7. PubMed ID: 22055352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.
    Nakashima H; Oniki K; Nishimura M; Ogusu N; Shimomasuda M; Ono T; Matsuda K; Yasui-Furukori N; Nakagawa K; Ishitsu T; Saruwatari J
    PLoS One; 2015; 10(10):e0141266. PubMed ID: 26484865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease in adolescents receiving valproic acid.
    Verrotti A; Agostinelli S; Parisi P; Chiarelli F; Coppola G
    Epilepsy Behav; 2011 Feb; 20(2):382-5. PubMed ID: 21256090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
    Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
    Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update.
    Guo HL; Jing X; Sun JY; Hu YH; Xu ZJ; Ni MM; Chen F; Lu XP; Qiu JC; Wang T
    Curr Pharm Des; 2019; 25(3):343-351. PubMed ID: 30931853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy.
    Ben Mahmoud L; Hakim A; Ghozzi H; Atheymen R; Sahnoun Z; Zeghal K
    Rev Neurol (Paris); 2017 Mar; 173(3):159-163. PubMed ID: 28320517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic-acid-induced thrombocytopenia and hepatotoxicity: discontinuation of treatment?
    Lackmann GM
    Pharmacology; 2004 Feb; 70(2):57-8. PubMed ID: 14685007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients With Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy.
    Ma B; Yang K; Li X; Su N; Yu T; Zou Y; Xu X; Wang F; Cheng J; Yan Z; Chen T; Zhang L
    Ther Drug Monit; 2024 Aug; 46(4):503-511. PubMed ID: 38287884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalase C-262T Polymorphism Is a Risk Factor for Valproic Acid-Induced Abnormal Liver Function in Chinese Patients With Epilepsy.
    Ma L; Pan Y; Sun M; Shen H; Zhao L; Guo Y
    Ther Drug Monit; 2019 Feb; 41(1):91-96. PubMed ID: 30422963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
    Bondareva IB; Jelliffe RW; Andreeva OV; Bondareva KI
    J Clin Pharm Ther; 2011 Oct; 36(5):625-36. PubMed ID: 21062333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.